Cadrenal Therapeutics, Inc. (CVKD)
After hours:
- PR Newswire
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with rare cardiovascular conditions, today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.
- Simply Wall St.
Favourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired Stock
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
- PR Newswire
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, will present at Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18, 2024 at 1:00pm ET. The formal presentation will feature a fireside style Q&A session with questio
